Tablet
TABRECTA TABLETS 150MG
Summary
TABRECTA TABLETS 150MG — Tablet containing capmatinib (as hydrochloride). Hong Kong Registration No. HK-66992. Certificate Holder: NOVARTIS PHARMACEUTICALS (HK) LIMITED. Date of Registration: 26 Feb, 2021.
Product NameTABRECTA TABLETS 150MG
Registration No.HK-66992
Certificate HolderNOVARTIS PHARMACEUTICALS (HK) LIMITED
Holder AddressSUITES 2303-2308, 23/F, NO.1111, KING'S ROAD, TAI KOO SHING, HONG KONG
Ingredientscapmatinib (as hydrochloride)
Dosage FormTablet
Legal ClassificationPart 1, Schedule 1 & Schedule 3 Poison
Sale RequirementPrescription only Medicines
Date of Registration26 Feb, 2021
ATC codesL01EP01
ATC Classification
ATC level 1
L Antineoplastic and Immunomodulating Agents
All ATC groupsL01
本頁為藥物資料查詢工具，並非藥物廣告、推廣或醫療建議。所有資料取自香港特別行政區衞生署藥物辦公室之公開資料，僅供參考；一切以藥物辦公室官方公布為準。 本頁不提供任何療效、適應症或治療用途之陳述。用藥前請諮詢醫生或註冊藥劑師。 本網站遵守香港法例第 231 章《不良廣告（醫藥）條例》之規管。